·   Log in

Archive for November 2nd, 2009

Flu vaccine for elderly JRV-100 in clinical trials: Juvaris Biotherapeutics

Monday, November 2, 2009 16:27

JVRS-100, a seasonal influenza vaccine for the elderly from Juvaris BioTherapeutics, Inc is currently undergoing human studies. Juvaris BioTherapeutics, Inc has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population. “There is a significant need to ...

This was posted under category: Biotech  |  Read Full Story  |  0 Comments

Prostate cancer vaccine Provenge (sipuleucel-T) to hit markets soon

Monday, November 2, 2009 16:22

Provenge (sipuleucel-T), a vaccine to treat prostate cancer from Dendreon Corporation may reach market within a year's time.

This was posted under category: Biotech  |  Read Full Story  |  2 Comments

Ranbaxy exits Vietnam business; expects US FDA will lift ban on Dewas facility soon

Monday, November 2, 2009 15:22

Daiichi Sankyo-controlled Ranbaxy Laboratories has sold its Vietnam business, as part of the company's ongoing restructuring operations. Ranbaxy may soon sell another of its business soon as it wants to divest of some of its loss making businesses, Ranbaxy CEO and MD Atul Sobti has stated. “We have divested the Vietnam operations ...

This was posted under category: Industry  |  Read Full Story  |  0 Comments

Wockhardt’s Q3 2009 net falls by Rs 54 crore

Monday, November 2, 2009 14:45

Indian generic major Wockhardt announced a 2.2 percent growth in consolidated sales revenues to stand at Rs 923 crore (about $197.25 million) for the third quarter ended September 30, 2009 over the corresponding quarter of 2008.

This was posted under category: Industry  |  Read Full Story  |  0 Comments
Tagged with: ,

Lupin moves US FDA to block cefixime (Suprax) oral suspension generics from rivals including Orchid Pharma

Monday, November 2, 2009 14:22

India' Lupin has approached the US Food & Drug Administration (US FDA) asking not to approve generic versions of antibiotic cefixime in oral suspension from companies including Orchid Pharma unless their products meet ``the same standards that the Lupin drug had to meet'', reports said.

This was posted under category: Industry  |  Read Full Story  |  0 Comments